Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTwist Bioscience Corp

Twist Bioscience Corp

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
120.79 USD 0.18 ( 0.15%)
Last update at 2026-11-06T21:00:00Z
VOLUME
2054516
Market Cap
2471.11M

Momentum Score

…

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
116.50
Low
130.90
High
52 Week Price Range
14.42
Low
50.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Twist Bioscience manufactures synthetic DNA on a proprietary silicon-based platform and supplies oligonucleotides and related products to biotech, pharmaceutical, diagnostics and synthetic-biology firms. Long-term growth may be supported by rising demand for gene synthesis in drug discovery, diagnostics and DNA data storage, scale benefits from high-throughput manufacturing and commercial partnerships, making the company a way to gain platform-driven exposure to expanding genomics applications.

Key risks include intense competition, execution and scaling challenges, continued unprofitable operations and capital needs, customer concentration and potential regulatory or technological shifts that could reduce demand.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
120.61
Dividend Yield
-
Revenue TTM
277.49M
Revenue Per Share
4.83
Gross Profit TTM
84.23M
Debt / Equity
0.15
ROE
-30.40%
Net Debt
-192.40M
ROCE
-30.89%
Diluted EPS TTM
-3.38

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax -203.47M -228.27M -154.03M -139.55M -107.38M
Net income -204.62M -217.86M -152.10M -139.93M -107.67M
Selling general administrative 189.74M 212.95M 135.90M 103.27M 80.13M
Gross profit 89.73M 84.23M 51.71M 28.69M 6.96M
Reconciled depreciation - 16.51M 9.75M 6.68M 6.11M
Ebit -217.16M -249.02M -153.26M -117.58M -108.85M
Ebitda -193.21M -247.05M -154.19M -116.26M -106.08M
Depreciation and amortization 23.95M 1.98M -0.94M 1.32M 2.77M
Non operating income net other - 6.58M -0.94M 1.32M 2.77M
Operating income -217.16M -249.02M -153.26M -117.58M -108.85M
Other operating expenses 452.01M 452.59M 285.59M 207.68M 163.24M
Interest expense 0.01M 0.08M 0.37M 0.79M 1.29M
Tax provision 1.15M -10.41M -1.93M 0.38M 0.29M
Interest income 14.37M 3.06M 0.43M 1.50M 3.03M
Net interest income 14.36M 2.98M 0.07M 0.71M 1.74M
Non recurring - - - 22.50M -
Income tax expense 1.15M -10.41M -1.93M 0.38M 0.29M
Total revenue 245.11M 203.56M 132.33M 90.10M 54.38M
Total operating expenses 296.63M 333.26M 204.97M 146.27M 115.81M
Cost of revenue 155.38M 119.33M 80.62M 61.41M 47.43M
Total other income expense net -10.92M 20.75M -0.77M -21.97M 1.47M
Net income from continuing ops -204.62M -217.86M -152.10M -139.93M -107.67M
Net income applicable to common shares - -217.86M -152.10M -139.93M -107.67M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 776.40M 961.38M 702.10M 398.88M 186.99M
Intangible assets 54.48M 59.74M 18.26M 0.31M 0.51M
Other current assets 11.72M 11.91M 8.28M 6.20M 2.59M
Total liab 152.97M 171.99M 121.28M 62.62M 34.91M
Total stockholder equity 623.43M 789.38M 580.82M 336.26M 152.08M
Other current liab 7.80M 53.45M 9.62M 2.61M 0.82M
Common stock - 789.38M 580.82M 336.26M -186.99M
Capital stock - 0.00M 0.00M 0.00M 0.00M
Retained earnings -1033.03M -828.42M -610.55M -458.45M -318.52M
Other liab - 0.06M 5.07M 0.35M 0.16M
Good will 85.81M 85.81M 22.43M 1.14M 1.14M
Other assets - -0.00M 49.90M 3.40M 4.38M
Cash 286.47M 378.69M 465.83M 93.67M 46.73M
Total current liabilities 73.32M 90.66M 63.05M 36.03M 30.35M
Current deferred revenue 36.57M 3.48M 28.76M 18.85M 16.44M
Net debt -192.40M -283.77M -402.91M -57.69M -39.00M
Short term debt 14.90M 13.64M 9.77M 9.74M 3.33M
Short long term debt - - 1.55M 3.33M 3.33M
Short long term debt total 94.07M 94.91M 62.92M 35.98M 7.73M
Other stockholder equity 1657.22M 1619.64M 1190.83M 794.63M 283.43M
Property plant equipment - 214.39M 44.12M 25.47M 20.84M
Total current assets 424.26M 596.48M 546.50M 334.87M 160.13M
Net tangible assets - 789.38M 540.12M 334.82M 150.44M
Short term investments 49.94M 126.28M 12.03M 196.34M 91.37M
Net receivables 44.06M 40.29M 28.55M 26.38M 12.10M
Long term debt - - - 1.40M 4.40M
Inventory 32.06M 39.31M 31.80M 12.29M 7.33M
Accounts payable 14.05M 20.09M 14.90M 4.83M 9.76M
Accumulated other comprehensive income -0.76M -1.84M 0.55M 0.09M 0.18M
Retained earnings total equity - -828.42M -610.55M -458.45M -318.52M
Non currrent assets other 8.49M 4.96M 9.20M 3.40M 4.38M
Non current assets total 352.15M 364.89M 155.60M 64.01M 26.86M
Capital lease obligations 94.07M 94.91M 61.37M 31.25M -
Long term debt total - - - 1.40M 4.40M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments - -117.16M 183.70M -104.78M -90.07M
Change to liabilities - 7.38M 19.02M -1.71M 12.30M
Total cashflows from investing activities - -232.93M 156.16M -114.65M -104.81M
Net borrowings - -1.56M -3.33M -3.33M -2.50M
Total cash from financing activities 0.91M 270.53M 329.18M 303.73M 158.58M
Change to operating activities - 4.42M 3.77M -0.44M 7.71M
Net income -204.62M -217.86M -152.10M -139.93M -107.67M
Change in cash -90.98M -87.10M 373.11M 46.85M -34.14M
Begin period cash flow 380.26M 467.36M 94.25M 47.40M 81.54M
End period cash flow 289.28M 380.26M 467.36M 94.25M 47.40M
Total cash from operating activities -142.47M -124.39M -112.24M -142.25M -87.94M
Issuance of capital stock - 269.82M 323.86M 295.56M 156.21M
Depreciation 29.31M 16.51M 9.75M 6.68M 6.11M
Other cashflows from investing activities - -13.91M -0.48M - 0.02M
Change to inventory 7.24M -7.54M -19.49M -4.96M -1.30M
Change to account receivables -4.32M -9.62M -2.20M -14.27M -6.68M
Sale purchase of stock -4.41M -7.75M -10.85M -2.42M 161.08M
Other cashflows from financing activities 5.32M 10.02M 19.50M 13.92M 4.87M
Change to netincome - 82.32M 37.10M 17.25M 11.59M
Capital expenditures 27.78M 101.86M 27.06M 9.87M 14.76M
Change receivables - -9.62M -2.20M -14.27M -6.68M
Cash flows other operating - 10.67M -5.00M -5.28M -1.32M
Cash and cash equivalents changes - -86.78M 373.09M 46.83M -34.17M
Change in working capital 0.41M -5.36M -9.38M -25.18M 3.00M
Stock based compensation 30.28M 79.66M 37.00M 17.10M 11.17M
Other non cash items 2.56M 2.66M 1.86M -0.71M 0.52M
Free cash flow -170.25M -226.24M -139.31M -152.12M -102.69M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TWST
Twist Bioscience Corp		 0.18
0.15%		 120.79 - - 6.76 3.01 5.93 -9.02
TMO
Thermo Fisher Scientific Inc		 17.82
2.63%		 694.76 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 3.91
1.73%		 230.25 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 25.45 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.31
1.23%		 24.85 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Twist Bioscience Corp

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

681 Gateway Boulevard, South San Francisco, CA, United States, 94080

800 719 0671

https://www.twistbioscience.com

919

Name Title Year Born
Dr. Emily Marine Leproust Ph.D. Co-Founder, Chairman & CEO 1973
Dr. Patrick John Finn Ph.D. Pres & COO 1972
Mr. James M. Thorburn Chief Financial Officer 1956
Dr. William Charles Banyai Ph.D. Sr. VP of Advanced Devel., GM of Data Storage & Director 1955
Mr. Kevin B. Yankton VP & Chief Accounting Officer 1967
Mr. Siyuan Chen Chief Technology Officer NA
Dr. Aaron K. Sato Ph.D. Chief Scientific Officer NA
Mr. Dennis Cho Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer 1971
Ms. Paula Green Sr. VP of HR 1968
Ms. Erin Smith Sr. VP of Gov. Affairs & Public Policy NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…